R. M. Borzilleri

机构：Bristol-Myers Squibb (Germany), Bristol-Myers Squibb (Sweden) · ORCID：0000-0002-9210-782X

发表论文 195 篇 · 总被引 5455 次 · h-index 33

代表论文

• Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form (2018 · Proceedings of the National Academy of Sciences · 被引 212)
• Decarboxylative Peptide Macrocyclization through Photoredox Catalysis (2016 · Angewandte Chemie International Edition · 被引 150)
• Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGFβRI) (2018 · Bioorganic & Medicinal Chemistry · 被引 37)
• DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell–mediated antitumor immunity (2023 · Science Translational Medicine · 被引 29)
• Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology Agents (2018 · ACS Medicinal Chemistry Letters · 被引 29)
• Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent (2020 · ACS Medicinal Chemistry Letters · 被引 28)